

## RESEARCH ARTICLE

# Quantifying early COVID-19 outbreak transmission in South Africa and exploring vaccine efficacy scenarios

Zindoga Mukandavire<sup>1,2</sup>, Farai Nyabadza<sup>3</sup>, Noble J. Malunguza<sup>4</sup>, Diego F. Cuadros<sup>5,6</sup>, Tinevimbo Shiri<sup>7</sup>, Godfrey Musuka<sup>8\*</sup>

**1** Centre for Data Science, Coventry University, Coventry, United Kingdom, **2** School of Computing, Electronics and Mathematics, Coventry University, Coventry, United Kingdom, **3** Department of Mathematics and Applied Mathematics, University of Johannesburg, Johannesburg, South Africa, **4** Department of Insurance and Actuarial Science, National University of Science and Technology, Bulawayo, Zimbabwe, **5** Department of Geography and Geographic Information Science, University of Cincinnati, Cincinnati, OH, United States of America, **6** Health Geography and Disease Modeling Laboratory, University of Cincinnati, Cincinnati, OH, United States of America, **7** Liverpool School of Tropical Medicine, Liverpool, England, United Kingdom, **8** ICAP at Columbia University, Harare, Zimbabwe

\* [gm2660@cumc.columbia.edu](mailto:gm2660@cumc.columbia.edu)



## OPEN ACCESS

**Citation:** Mukandavire Z, Nyabadza F, Malunguza NJ, Cuadros DF, Shiri T, Musuka G (2020) Quantifying early COVID-19 outbreak transmission in South Africa and exploring vaccine efficacy scenarios. PLoS ONE 15(7): e0236003. <https://doi.org/10.1371/journal.pone.0236003>

**Editor:** Jeffrey Shaman, Columbia University, UNITED STATES

**Received:** April 23, 2020

**Accepted:** June 27, 2020

**Published:** July 24, 2020

**Copyright:** © 2020 Mukandavire et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Data used for model fitting is available in the Supporting Information files. These data are also freely available online from the South African Department of Health ([https://www.gov.za/newsroom?title\\_field\\_value=mkhize&field\\_gcis\\_speech\\_category\\_tid=All&field\\_gcis\\_speech\\_government\\_lv1\\_tid=All&field\\_gcis\\_speech\\_date\\_value\\_1\[min\]\[date\]=&field\\_gcis\\_speech\\_date\\_value\\_1\[max\]\[date\]=](https://www.gov.za/newsroom?title_field_value=mkhize&field_gcis_speech_category_tid=All&field_gcis_speech_government_lv1_tid=All&field_gcis_speech_date_value_1[min][date]=&field_gcis_speech_date_value_1[max][date]=)).

**Funding:** The author(s) received no specific funding for this work.

## Abstract

The emergence and fast global spread of COVID-19 has presented one of the greatest public health challenges in modern times with no proven cure or vaccine. Africa is still early in this epidemic, therefore the extent of disease severity is not yet clear. We used a mathematical model to fit to the observed cases of COVID-19 in South Africa to estimate the basic reproductive number and critical vaccination coverage to control the disease for different hypothetical vaccine efficacy scenarios. We also estimated the percentage reduction in effective contacts due to the social distancing measures implemented. Early model estimates show that COVID-19 outbreak in South Africa had a basic reproductive number of 2.95 (95% credible interval [CrI] 2.83–3.33). A vaccine with 70% efficacy had the capacity to contain COVID-19 outbreak but at very higher vaccination coverage 94.44% (95% CrI 92.44–99.92%) with a vaccine of 100% efficacy requiring 66.10% (95% CrI 64.72–69.95%) coverage. Social distancing measures put in place have so far reduced the number of social contacts by 80.31% (95% CrI 79.76–80.85%). These findings suggest that a highly efficacious vaccine would have been required to contain COVID-19 in South Africa. Therefore, the current social distancing measures to reduce contacts will remain key in controlling the infection in the absence of vaccines and other therapeutics.

## Introduction

The Coronavirus Disease 2019 (COVID-19) originated in Wuhan, China, in December 2019 and has rapidly spread around the world [1]. As this is a new and novel virus, there is a huge scientific evidence gap and therefore limited understanding of the epidemiology of SARS-CoV-2, the pathogen that causes the disease COVID-19. Currently, the epicentre of the virus is


**Competing interests:** The authors have declared that no competing interests exist.

in Europe and New York in the United States of America [2]. In Africa, the virus is just starting to set its foothold, with South Africa now reporting the majority of cases in the continent. The first case of the COVID-19 in South Africa was reported on the 5<sup>th</sup> of March 2020 [3]. Measures to contain the epidemic culminated in the declaration of the state of disaster leading to a national *lockdown* on the 26<sup>th</sup> of March 2020 with Gauteng, Western Cape, KwaZulu-Natal and the Free State provinces reporting most of the COVID-19 cases. The map in Fig 1 shows the distribution of COVID-19 confirmed cases in South Africa before the government mandated a *lockdown*. Gauteng province appeared to be the “*epicentre*” of COVID-19 in South Africa for a number of reasons. First, the province has the largest population density [4, 5] and the urban population is poor with 20% of its population being food insecure [4]. Second, Gauteng province has two international airports including OR Tambo International Airport handling over 21 million passengers annually [6]. Third, the volume of people that use public transport runs into millions daily creating social networks and patterns that are key in accelerating the spread of the disease. Finally, the province is the country’s economic hub, and many people (including international visitors) travel in and out of the province daily [4]. With the majority of confirmed cases early in the outbreak having been linked to international travel [7], it is not surprising that the most affected provinces (Gauteng, Western Cape and KwaZulu-Natal) have international airports with direct flights to affected global regions (Fig 1). The cases in the Free State province have mainly been attributed to a cluster transmission resulting from a mega church gathering [8].

With COVID-19 having been declared a global pandemic [9] and the urgent need to have an effective vaccine to control the pandemic [10], there is a need to understand the utility of mass vaccination campaigns for this pandemic. Critical in the early stages of the disease is the need to clearly understand the spectrum of disease severity and transmission characteristics of the disease in order to identify optimal control measures. Many of the control measures suggested for this pandemic have been attributed to the lessons learnt in Wuhan, China [11]. The challenges associated with real-time analysis of an evolving epidemic are well articulated in [12]. These include testing capacity and delayed appearance of symptoms and asymptomatic carriage. The impact of COVID-19 on South Africa may differ from that on China and other regions such as Europe and North America. South Africa has unique circumstances, for example, it has the highest numbers of people living with HIV, with a significant proportion not on treatment, and one of the largest tuberculosis (TB) burdens in the world [13, 14]. Moreover, underlining disease conditions such as diabetes, hypertension and chronic obstructive pulmonary disease are prevalent in South African and these are known to be risk factors for COVID-19 infection and mortality [15]. The age distribution for South Africa is also different from China and Europe as its young population accounts for the majority of the population [16].

Data from China and other settings have shown that SARS-CoV-2 is more infectious than influenza, and has an incubation period of about 5 days (median time) and a doubling time of 3 days [17, 18]. However, we have a limited understanding of the infectiousness of the virus in settings with different populations and a huge burden of other chronic conditions such as Africa. Mathematical models provide important insights in the understanding of emerging infectious diseases and informing public health policies. Several mathematical models have been used to understand COVID-19 transmission dynamics and inform public health policy [12, 19, 20, 21, 22]. The reproductive numbers of the COVID-19 epidemic in China have been determined in several modelling studies (Table 1).

Here, we adapt a susceptible-exposed-infected-removed (*SEIR*) compartmental model to quantify early transmissibility of COVID-19 in South Africa and explore the potential utility of a vaccine in containing the disease. The *SEIR* model has been used to model respiratory infections including Middle East Respiratory Syndrome (MERS) [23, 24], COVID-19 in Wuhan



**Fig 1. COVID-19 cases distribution in South Africa by 27 March 2020.** Map was created using ArcGIS® by ESRI version 10.5 (<http://www.esri.com>).

<https://doi.org/10.1371/journal.pone.0236003.g001>

**Table 1. COVID-19 reproductive numbers from modelling studies in China.**

| Study                   | Location           | Reproductive number estimate |
|-------------------------|--------------------|------------------------------|
| Wu <i>et al.</i> [28]   | Wuhan              | 2.68 [2.47–2.86]             |
| Shen <i>et al.</i> [29] | Hubei province     | 6.49 [6.31–6.66]             |
| Liu <i>et al.</i> [30]  | China and overseas | 2.90 [2.32–3.63]             |
| Majumder and Mandl [31] | Wuhan              | 2.55 [2.00–3.10]             |
| Read <i>et al.</i> [32] | China              | 3.11 [2.39–4.13]             |
| Zhao <i>et al.</i> [33] | China              | 2.24 [1.96–2.55]             |
| Qun <i>et al.</i> [34]  | China              | 2.2 [1.40–3.90]              |
| Tang <i>et al.</i> [35] | China              | 6.47 [5.71–7.23]             |
| Imai <i>et al.</i> [36] | Wuhan              | 2.5 [1.50–3.50]              |

<https://doi.org/10.1371/journal.pone.0236003.t001>

China [11], influenza [25, 26] and global tracking of COVID-19 [27]. In addition, we estimate the reduction in effective contacts after the implementation of the severe and extreme shut-down of the society, and this is critical in determining the impact of social distancing in the South African context.

## Methods

We use a standard deterministic compartmental *SEIR* model to simulate COVID-19 in South Africa. The model classifies the human population into four epidemiological compartments at any time  $t$ , the susceptible  $S(t)$ , exposed  $E(t)$ , infected  $I(t)$  and the recovered  $R(t)$ . The total population is thus given by  $N(t) = S(t) + E(t) + I(t) + R(t)$ . Susceptible individuals are infected upon interaction with infectious COVID-19 individuals and the rate of daily generation of newly infected cases is given by  $\lambda(t) = \beta S(t)I(t)/N$ , where the parameter  $\beta$  is the effective contact rate, *i.e.* the contact that will result in an infection. The lockdown effect is modelled with parameter,  $\epsilon \in (0, 1)$  where  $\epsilon \simeq 0$  implies an ineffective *lockdown* and  $\epsilon \simeq 1$  implies a completely effective *lockdown*. The effective contact reduction term multiplies the effective contact rate in the model to give  $(1 - \epsilon)\beta$ . Exposed individuals in the  $E(t)$  compartment become infectious at a constant rate  $\sigma$  and move to the  $I(t)$  class. Infected individuals  $I(t)$ , recover at a constant rate  $\gamma$  to the removed class  $R(t)$ . The schematic model flow diagram is presented in [S1 Fig](#). The model assumptions result in the following system of differential equations.

$$\frac{dS}{dt} = -(1 - \epsilon) \frac{\beta SI}{N}, \quad \frac{dE}{dt} = (1 - \epsilon) \frac{\beta SI}{N} - \sigma E, \quad \frac{dI}{dt} = \sigma E - \gamma I, \quad \frac{dR}{dt} = \gamma I. \quad (1)$$

Following a similar approach in [37], we use a Markov Chain Monte Carlo (MCMC) within a Bayesian framework (in R FME package [38]) to fit the model to the cumulative data of confirmed COVID-19 cases in South Africa and estimate the magnitude of the epidemic using the basic reproductive number and quantify required vaccines' attributes to stem similar outbreaks. We used data on COVID-19 cases published by the South African Department of Health from the 5<sup>th</sup> of March 2020 to 28 March 2020 prior to the *lockdown* to estimate the basic reproductive number [39]. We set the model *lockdown* effect parameter  $\epsilon = 0$  when estimating the basic reproductive number. The percentage reduction in effective contacts after the *lockdown*  $\epsilon$  was estimated by fitting the model to cumulative COVID-19 cases reported a week after the *lockdown* (from 29<sup>th</sup> March to 11<sup>th</sup> April 2020). Cumulative data for COVID-19 cases reported in South Africa from the 5<sup>th</sup> March to 11<sup>th</sup> April 2020 is shown in [S1 Table](#).

In the fitting, we set the *lockdown* effect parameter  $\epsilon = 0$  and varied  $\beta$ ,  $\sigma$ ,  $\gamma$  (within parameter ranges in [S2 Table](#)) and initial infected population in order to estimate the basic reproductive number. In estimating the *lockdown* effect, we varied  $\epsilon$  and kept parameters used to estimate the basic reproductive number constant. Gaussian likelihood was used to draw model parameter posteriors assuming uniform non-informative priors while the variances were regarded as nuisance parameters. The MCMC chain was generated with at least 100 000 runs for the final fitting excluding the burn-in period. Chain convergence was examined visually and using the Coda R package [40]. Uncertainty of each estimated parameter was evaluated by analysing the MCMC chains and calculating the 2.5% and 97.5% quantiles to give the 95% credible interval (CrI).

The basic reproductive number ( $\mathcal{R}_0$ ), is as a measure of the average number of secondary cases generated by a primary case and is an important statistic for quantifying intervention programmes [41, 42]. Using an intuitive mathematical approach, the reproductive number of model system (1) is given by  $\mathcal{R}_0 = \beta/\gamma$ . The corresponding minimum vaccination coverage ( $c$ ) for COVID-19 vaccine for different vaccine efficacy scenarios was estimated using the

**Table 2. Estimates of effective contact rate ( $\beta$ ), the incubation period ( $1/\sigma$ ), infectious period ( $1/\gamma$ ), the percentage reduction in effective contacts ( $\epsilon$ ) and basic reproductive number ( $\mathcal{R}_0$ ).**

| Parameter description                                     | Estimated values [95% CrIs]        |
|---|------------------------------------|
| <b>Before lockdown</b>                                    |                                    |
| Effective contact rate ( $\beta$ )                        | 1.30 [1.21–1.39] day <sup>-1</sup> |
| Incubation period ( $1/\sigma$ )                          | 3.21 [3.04–3.44] days              |
| Infectious period ( $1/\gamma$ )                          | 2.27 [2.04–2.74] days              |
| Basic reproductive number ( $\mathcal{R}_0$ )             | 2.95 [2.83–3.33]                   |
| <b>After lockdown</b>                                     |                                    |
| Percentage reduction in effective contacts ( $\epsilon$ ) | 80.31 [79.76–80.85]%               |


<https://doi.org/10.1371/journal.pone.0236003.t002>

mathematical expression  $c \geq (1 - \mathcal{R}_0^{-1})/s$  where  $s$  the proportional reduction of the susceptibility for individuals partially immunized.

## Results


Estimates of effective contact rate ( $\beta$ ), the incubation period ( $1/\sigma$ ), infectious period ( $1/\gamma$ ), the percentage reduction in effective contacts ( $\epsilon$ ) and the basic reproductive number,  $\mathcal{R}_0$  for South Africa are shown in Table 2. The mathematical model (of the SEIR type) was fitted to the cumulative COVID-19 cases for South Africa at the national level (Fig 2(A)). We estimated an effective contact rate 1.30 (95% CrI 1.21–1.39) per day, incubation period of 3.21 days (95% CrI 3.04–3.44 days), infectious period of 2.27 days (95% CrI 2.04–2.74 days) and  $\mathcal{R}_0$  of 2.95 (95% CrI 2.83–3.33) before the lockdown. The result  $\mathcal{R}_0 > 1$  clearly shows disease sustainability in the country.

Estimates of  $\mathcal{R}_0$  were used to conduct sensitivity analysis based on different COVID-19 vaccines' efficacy assumptions to explore possible scenarios that may arise from mass vaccination campaigns, as scientists attempt to develop effective vaccines for COVID-19 [43, 44]. The vaccine efficacy scenarios were assumed to vary in the range of 50–100% (Fig 2(B)). The results suggest that a vaccine with more than 70% efficacy could have the potential to contain the COVID-19 outbreak in South Africa but at extremely high vaccination coverage rates of 94.44% (95% CrI 92.44–99.92%). As expected, vaccination coverage for epidemic control decreases with an increase in vaccine efficacy, with a vaccine of 100% efficacy requiring



**Fig 2.** (a) Shows COVID-19 model fitting to cumulative cases where the green region is the 95% CrIs, the dashed brown line is the best model fit and the blue circles are the reported data for the cumulative number of COVID-19 cases in South Africa. (b) Shows the sensitivity analysis plot showing different vaccination coverages for different COVID-19 vaccine efficacy for South Africa. The dark grey regions are the 95% CrIs and the black line is the median.

<https://doi.org/10.1371/journal.pone.0236003.g002>



**Fig 3.** The graph shows COVID-19 model fitting to cumulative cases where the green region is the 95% CrIs, the dashed brown line is the best model fit and the blue circles mark are the reported data for the cumulative number of COVID-19 cases in South Africa. The red vertical line denotes the time when the *lockdown* was implemented by the government. The dark green region show the trajectory the epidemic would have taken if a *lockdown* was not implemented and the light green region show the trajectory of the epidemic after the implementation of a *lockdown*.

<https://doi.org/10.1371/journal.pone.0236003.g003>

66.10% (95% CrI 64.71–69.95%) coverage which is achievable under routine immunisation campaigns [45].

We also quantified the percentage reduction in effective contacts as a result of the *lockdown* mandated by the government of South Africa. Fig 3 shows that the epidemic is slowing down after the implementation of a *lockdown*. The results showed that the *lockdown* resulted in 80.31% (95% CrI 79.76–80.85%) reduction in effective contacts (Table 2) and consequently resulted in a reduction in the number of COVID-19 cases reported in the first two weeks of implementation. This confirms results in China that demonstrated the importance of quarantine, social distancing, and isolation in containing the pandemic [46].

## Discussion

COVID-19 has spread rapidly globally assisted by air travel in an increasingly connected world [47, 48]. Globally most countries, including South Africa, have adopted one form or another of the *lockdown* approaches in an attempt to curb disease transmission within their borders [11, 49, 50]. Our model estimate of  $\mathcal{R}_0 > 1$  confirms COVID-19 persistence in South Africa and indicate that the outbreak has the momentum to rapidly spread and spill over to other geographic regions of the country, in particular if the coming winter season (May to July) presents ideal environmental conditions for persistence of the virus. The estimate of  $\mathcal{R}_0$  for South Africa is in a similar range published for COVID-19 in other modelling studies (Table 1).

Hypothetical scenarios on vaccine efficacy demonstrated that, a vaccine of at least 70% efficacy would have been sufficient to contain the spread of COVID-19 in South Africa although at high vaccination coverage. However, it is important to note that expectations that the development of a highly effective vaccine for the novel-coronavirus will be achieved in the coming months are extremely optimistic, especially when considering that a vaccine has still not been

successfully created for viruses like HIV, severe acute respiratory syndrome (SARS) and MERS, with the HIV vaccine being in development for many years [44, 51]. Nevertheless, the huge global interest in quickly identifying an effective vaccine could increase the possibility that a successful vaccine candidate can be developed in the coming months [43]. Even when a safe and effective vaccine becomes available, there are several logistical and operational challenges that need to be addressed for successful deployment and for the vaccine to achieve the desired coverage [52, 53].

The modelled *lockdown* demonstrated 80.31% reduction in effective contacts, showing that it is an effective measure to bring the disease under control. However, the reduction in the number of daily reported cases should be interpreted with caution as this could also have been a result of many other factors such as reduced international travel to high-risk regions and behaviour change. As the epidemic continues to unfold, it remains to be seen what trend the epidemic will follow if local transmissions are sustained within South Africa. The implementation of this society shut down is not sustainable in the long run as it is unlikely to be tolerated for too long by the population. A vaccine would be an ideal preventative strategy for COVID-19 but it appears that it should be complemented with prevention approaches such as isolation, quarantine, personal hygiene and limitations of public gatherings in order to achieve optimal protection of the population in South Africa.

The economic and social burden of the disease continues to be felt and this likely to be enhanced by an extension of the current *lockdown* of 21 days by a further 2 weeks [54]. However it is unclear whether a *stringent lockdown* could be maintained for a longer period given the socio-economic challenges of the country where a significant percent of adults are involved in informal employment and others have jobs that do not allow them to work from home. This could affect the effectiveness of the *lockdown* in many of the townships as individuals will have to ease *lockdown* conditions in order to be economically active and prevent financial woes on individuals in urban communities. While the epidemic seems to have slowed down as a result of the *lockdown* (Fig 3), there is need for continued scientific investigation including explorations through mathematical models to monitor the trend with the aim of informing public health policy in the short-term.

The study has some limitations. The estimate of the reproductive number is based on available data and this estimate could possibly change depending on the quality of the data from the start of the epidemic (with possible under-reporting of cases in the initial phases of the epidemic). We note that spatial modelling mainly in the affected provinces would have been ideal but we did not have good data on a finer resolution to effectively parameterise a spatial model but as the epidemic evolves, nascent data on local COVID-19 transmission in South Africa is becoming available. We used a simple mathematical model without other population demographics as these were not important for short-term prediction [55] and such models are also important when epidemiological and clinical disease characteristics of the disease are not well established as is the case for COVID-19 [56]. The simple model is only intended to give preliminary estimates for an epidemic that is evolving and whose trend has the potential to change dramatically overtime. However, it would be interesting to see how our results will change when a more complicated model is used. Despite these shortfalls, findings in this study are important in understanding the transmissibility of the virus and informing the development of robust COVID-19 prevention and control programmes in South Africa and outlining mass vaccination expectations.

The COVID-19 pandemic has continued to spread and causing many deaths than any infectious disease we have seen in recent years and this calls for an urgent and well-coordinated timely and effective public health response. Currently there is no proven treatment or vaccines for COVID-19 and countries have embraced quarantine, social distancing, and

isolation of infected individuals to contain the pandemic. Thus, as more setting-specific data about the transmission dynamics of the virus become available, the building of suitable mathematical models to weight out the impact of current public health control measures and explore the potential utility of anticipated biomedical interventions such as vaccines is paramount.

## Supporting information

**S1 Fig. Schematic COVID-19 model diagram outlining infection progression.** The arrows connecting compartments denote COVID-19 infection at rate  $\beta S(t)I(t)/N$ , progression to infectiousness  $\sigma E$  and recovery rate  $\gamma I$  respectively.

(DOCX)

**S1 Table. Cumulative COVID-19 cases for South Africa.** This data of cases reported from the 5<sup>th</sup> March to 11<sup>th</sup> April 2020 data.

(DOCX)

**S2 Table. COVID-19 model parameters and values.** \*We used population size for Gauteng, Western Cape, KwaZulu-Natal and Free State provinces in estimating national level estimates as these were the only provinces with COVID-19 cases in the early phases of the epidemic. Population estimates were based on the 2019 census [1].

(DOCX)

## Author Contributions

**Conceptualization:** Zindoga Mukandavire, Farai Nyabadza, Noble J. Malunguza, Diego F. Cuadros, Tinevimbo Shiri, Godfrey Musuka.

**Data curation:** Farai Nyabadza.

**Formal analysis:** Zindoga Mukandavire, Diego F. Cuadros.

**Supervision:** Farai Nyabadza, Godfrey Musuka.

**Writing – original draft:** Zindoga Mukandavire, Farai Nyabadza, Diego F. Cuadros, Tinevimbo Shiri, Godfrey Musuka.

**Writing – review & editing:** Zindoga Mukandavire, Farai Nyabadza, Noble J. Malunguza, Diego F. Cuadros, Tinevimbo Shiri, Godfrey Musuka.

## References

1. World Health Organisation, "Coronavirus disease 2019 (COVID-19) Situation Report– 62. March 2020," Retrieved March 30, 2020 from <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>, 2019.
2. Dong E., Du H. and Gardner L., "An interactive web-based dashboard to track COVID-19 in real time," *The Lancet Infectious Diseases*, [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1), 2020.
3. South African Government, "First case of Covid-19 Coronavirus reported in SA, Retrieved April 2, 2020, from <https://www.gov.za/speeches/health-reports-first-case-covid-19-coronavirus-5-mar-2020-0000>," 2020.
4. G. Nicolson, "Battleground Gauteng: Epicentre of the pandemic, Retrieved April 2, 2020, from <https://www.dailymaverick.co.za/article/2020-03-27-battleground-gauteng-epicentre-of-the-pandemic>," 2020.
5. STATS SA, "Statistics South Africa," Retrieved March 31, 2020, from [http://cs2016.statssa.gov.za/?portfolio\\_page=census-2011-fact-sheet](http://cs2016.statssa.gov.za/?portfolio_page=census-2011-fact-sheet), 2016.
6. Wikipedia, "O. R. Tambo International Airport, Retrieved April 13, 2020, from [https://en.wikipedia.org/wiki/O.\\_R.\\_Tambo\\_International\\_Airport](https://en.wikipedia.org/wiki/O._R._Tambo_International_Airport)".



7. National Institute for Communicable Diseases, "National Institute for Communicable Diseases, Covid-19 update: 274 confirmed cases– 76% have history of travel, Retrieved April 9, 2020, from <https://www.nicd.ac.za/covid-19-update-24/>, 2020.
8. F. Haffajee, "Free State races to curb Covid-19 outbreak as Angus Buchan tests positive and country cases rise to 927," Retrieved March 30, 2020, from <https://www.dailymaverick.co.za/article/2020-03-26-free-state-races-to-curb-covid-19-outbreak-as-angus-buchan-tests-positive-and-coun-and-country-cases-rise-to-927/>, 2020.
9. World Health Organisation, "WHO Director-General's opening remarks at the media briefing on COVID-19, Retrieved April, 09, 2020 from <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19>," 2020.
10. Yamey G., Schäferhoff M. and et al., "Ensuring global access to access to COVID-19 vaccines," *Lancet*, pp. S0140-6736(20)30763-7, 2020.
11. Lin Q. and et al., "A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action," *International Journal of Infectious Diseases*, <https://doi.org/10.1016/j.ijid.2020.02.058>, 2020.
12. Kucharski J., Russell T. W., Diamond C., Liu Y., E. J., Funk S., et al. "Early dynamics of transmission and control of COVID-19: a mathematical modelling study," *Lancet Infectious Diseases*, pp. S1473-3099(20)30, 2020.
13. World Health Organization, "Global tuberculosis report 2019," World Health Organization, Geneva, 2019.
14. Hansoti B., Mwinnyaa G., Hahn E. and et al., "Targeting the HIV Epidemic in South Africa: The Need for Testing and Linkage to Care in Emergency Departments," *EClinicalMedicine*, pp. (15),14–22, 2019.
15. L. Chutel and A. L. Dahir, "With Most Coronavirus Cases in Africa, South Africa Locks Down," Retrieved 02 April 2020 from <https://www.nytimes.com/2020/03/27/world/africa/south-africa-coronavirus.html>, 2020.
16. STATS SA, "Mid-year population estimates 2019, Retrieved April 13, 2020, from <https://www.statssa.gov.za/publications/P0302/P03022019.pdf>," 2019.
17. Lauer S. A., Grantz K. H., Bi Q., Jones F. K., Zheng Q., Meredith H. R., et al. "The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application," *Annals of Internal Medicine*, <https://doi.org/10.7326/M20-0504>, 2020. PMID: [32150748](https://pubmed.ncbi.nlm.nih.gov/32150748/)
18. K. Muniz-Rodriguez, G. Chowell, C. H. Cheung, D. Jia, P. Y. Lai, Y. Lee, et al. "Epidemic doubling time of the COVID-19 epidemic by Chinese province," medRxiv, Retrieved 13 April 2020, <https://www.medrxiv.org/content/10.1101/2020.02.05.20020750v4>, <https://doi.org/10.1101/2020.02.05.20020750>, 2020.
19. Zhao S. and Chen H., "Modeling the epidemic dynamics and control of COVID-19 outbreak in China," *Quantitative Biology*, pp. 11:1–9, 2020.
20. Cascella M., Rajnik M., Cuomo A., Dulebohn S. C. and Di Napoli R., "Features, Evaluation and Treatment Coronavirus (COVID-19)," In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; <https://www.ncbi.nlm.nih.gov/books>, 2020.
21. Zhu Z. B., Zhong C. K., Zhang K. X. and et al., "Epidemic trend of corona virus disease 2019 (COVID-19) in mainland China," *EPub*, p. 3; 54(0), 2020.
22. Roosa K., Lee Y., Luo R. and et al., "Real-time forecasts of the COVID-19 epidemic in China from February 5th to February 24th, 2020.," *Infectious Disease Modelling*, pp. 5:256–263, 2020. <https://doi.org/10.1016/j.idm.2020.02.002> PMID: [32110742](https://pubmed.ncbi.nlm.nih.gov/32110742/)
23. Kwon Chi-Myung and Jung J. U., "Applying discrete SEIR model to characterizing MERS spread in Korea," *International Journal of Modeling, Simulation, and Scientific Computing*, p. 7(4) 1643003, 2016.
24. Lin Q., Chiu A. P., Zhao S. and He D., "Modeling the spread of Middle East respiratory syndrome coronavirus in Saudi Arabia," *Statistical Methods in Medical Research*, pp. 27(7):1968–1978, 2018. <https://doi.org/10.1177/0962280217746442> PMID: [29846148](https://pubmed.ncbi.nlm.nih.gov/29846148/)
25. Etbajgha F. R., Willms A. and Poljak Z., "An SEIR model of influenza A virus infection and reinfection within a farrow-to-finish swine farm.," *PLoS ONE*, p. 13(9): e0202493, 2018. <https://doi.org/10.1371/journal.pone.0202493> PMID: [30248106](https://pubmed.ncbi.nlm.nih.gov/30248106/)
26. Leonenko N. V. and Ivanov S. V., "Fitting the SEIR model of seasonal influenza outbreak to the incidence data for Russian cities," *Russian Journal of Numerical Analysis and Mathematical Modelling*, pp. 31(5),1–7, 2016.
27. Binti Hamzah F. A. and et al., "CoronaTracker, World-wide COVID-19 Outbreak data analysis and prediction," *Bulletin of World Health Organisation*, 2020.

28. Wu J. T., Leung K. and Leung G. M., "Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study," *The Lancet*, [https://doi.org/10.1016/S0140-6736\(20\)30260-9](https://doi.org/10.1016/S0140-6736(20)30260-9), 2020.
29. M. Shen, Z. Peng, Y. Xiao and L. Zhang, "Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China," bioRxiv, Retrieved April 10, 2020, from <https://www.biorxiv.org/content/10.1101/2020.01.23.916726v1.abstract>, 2020.
30. T. Liu, J. Hu, M. Kang and et al., "Transmission dynamics of 2019 novel coronavirus (2019-nCoV)," bioRxiv, Retrieved April 10, 2020, from [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3526307](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3526307), 2020.
31. M. Majumder and K. D. Mandl, "Early transmissibility assessment of a novel coronavirus in Wuhan, China," SSRN, Retrieved April 10, 2020, from <https://ssrn.com/abstract=3524675>, 2020.
32. J. M. Read, J. R. E. Bridgen, D. A. T. Cummings, A. Ho and C. P. Jewell, "Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions," medRxiv, Retrieved April 12, 2020, from <https://www.medrxiv.org/CONTENT/10.1101/2020.01.23.20018549v2>, 2020.
33. Zhao S. and et al., "Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak," *International Journal of Infectious Diseases*, pp. 92, 214–217, 2020. <https://doi.org/10.1016/j.ijid.2020.01.050> PMID: 32007643
34. Qun L. and et al., "Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia," *New England Journal of Medicine*, <https://doi.org/10.1056/NEJMoa2001316>, 2020. PMID: 31995857
35. Tang B., Wang X., Li Q., Bragazzi N. L., Tang S., Xiao Y., et al. "Estimation of the transmission risk of the 2019-nCoV and its implication for public health interventions," *Journal of Clinical Medicine*, pp. 9(2), 462, 2020.
36. N. Imai, A. Cori and et al., "Report 3: transmissibility of 2019-nCoV. 2020. WHO Collaborating Centre for Infectious Disease Modelling," MRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College London, UK.
37. Mukandavire Z., Manangazira P., Nyabadza F., Cuadros D. F., Musuka G. and Morris J. G. Jr, "Stemming cholera tides in Zimbabwe through mass vaccination," *In: International Journal of Infectious Diseases*, (Accepted/In press), 2020.
38. Soetaert K. and Petzoldt T., "Inverse modelling, sensitivity and monte carlo analysis in R using package FME," *Journal of Statistical Software*, p. 33, 2010.
39. South African Government, "COVID-19 / Novel Coronavirus, Retrieved March 30, 2020, from <https://www.gov.za/Coronavirus>," 2020.
40. Plummer M., Best N., Cowles K. and Vines K., "CODA: convergence diagnosis and output analysis for MCMC," *R News*, p. 6(1): 7–11, 2006.
41. Mukandavire Z., Liao S., Wang J., Gaff H., Smith D. L. and Morris J. G. J., "Estimating the reproductive numbers for the 2008–2009 cholera outbreaks in Zimbabwe," *Proceedings of National Academic Science, USA*, vol. 108, no. 21, pp. 8767–8772., 2011.
42. Mukandavire Z., Smith D. L. and Morris J. G. Jr, "Cholera in Haiti: reproductive numbers and vaccination coverage estimates," *Scientific reports*, vol. 3, no. 997, pp. 3, 997, 2013.
43. Ahmed S. F., Quadeer A. A. and McKay M. R., "Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies," *Viruses*, p. 12(3):E254, 2020. <https://doi.org/10.3390/v12030254> PMID: 32106567
44. Yuen K. S., Ye Z. W., Fung S. Y., Chan C. P. and Jin D. Y., "SARS-CoV-2 and COVID-19: The most important research questions," *Cell Biosciences*, p. 10:40, 2020.
45. Peck M., Gacic-Dobo M., Diallo M. S., Nedelec Y., Sodha S. V. and Wallace A. S., "Global Routine Vaccination Coverage, 2018," *MMWR Morb Mortal Weekly Report*, p. (44):1010, 2019.
46. World Health Organisation, "Coronavirus disease 2019 (COVID-19), situation report-44," World Health Organisation, Geneva, 2019.
47. Gilbert M., Pullano G., Pinotti F. and et al., "Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study," *Lancet*, p. 395(10227):871–877, 2020. [https://doi.org/10.1016/S0140-6736\(20\)30411-6](https://doi.org/10.1016/S0140-6736(20)30411-6) PMID: 32087820
48. Haider N., Yavlinsky A., Simons D. and et al., "Passengers' destinations from China: low risk of Novel Coronavirus (2019-nCoV) transmission into Africa and South America," *Epidemiology and Infection*, p. 148:e41, 2020. <https://doi.org/10.1017/S0950268820000424> PMID: 32100667
49. Lau H., Khosrawipour V., Kocbach P. and et al., "The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China," *Journal of Travel Medicine*, <https://doi.org/10.1093/jtm/taaa037>, 2020.

50. Chen Z. L., Zhang Q., Lu Y. and et al, "Distribution of the COVID-19 epidemic and correlation with population emigration from wuhan, China [published online ahead of print, 2020 Feb 28]," *Chinical Medicine Journal (Engl)*, p. 10.1097/CM9.0000000000000782. <https://doi.org/10.1097/CM9.000>, 2020
51. J. Paton, "Coronavirus Vaccine in 18 Months? Experts Urge Reality Check," Bloomberg, Retrieved April 13, 2020 from <https://www.bloomberg.com/news/articles/2020-03-31/coronavirus-vaccine-is-coming-in-a-year-to-18-months-show-me>, 2020.
52. Equils O., Kellogg C., Baden L., Berger W. and Connolly S., "Logistical and structural challenges are the major obstacles for family medicine physicians' ability to administer adult vaccines," *Human vaccines & immunotherapeutics*, vol. 15, no. 3, pp. 637–642, 2019.
53. Johann van den Heever, "Operational Challenges of Vaccination, 10th Annual African Vaccinology Course (AAVC), Retrieved April 11, 2020, from [http://www.vacfa.uct.ac.za/sites/default/files/image\\_tool/images/210/AAVC2010-lecture-slides/Operational%20challenges%20of%20Vaccination%2](http://www.vacfa.uct.ac.za/sites/default/files/image_tool/images/210/AAVC2010-lecture-slides/Operational%20challenges%20of%20Vaccination%2)," University of Cape Town, Cape Town, 2014.
54. South African Government News Agency, "Nationwide lockdown extended by two weeks," SA [news.gov.za](https://www.sanews.gov.za), Retrieved April 11, 2020, from <https://www.sanews.gov.za/south-africa/nationwide-lockdown-extended-two-weeks>, Pretoria, 2020.
55. Grant H., Foss A. M., Watts C., Medley G. F. and Mukandavire Z., "Is modelling complexity always needed? Insights from modelling PrEP introduction in South Africa," *Journal of Public Health*, <https://doi.org/10.1093/pubmed/fdz178>, 2020.
56. Kolifarhood G., Aghaali M., Saadati H. M., Taherpour N., Rahimi S., Izadi N. and Nazari S. S. H., "Epidemiological and Clinical Aspects of COVID-19; a Narrative Review," *Archives of Academic Emergency Medicine*, p. 8(1), 2020.